The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Results from the BRESELIBET trial of brentuximab vedotin + chemotherapy for R/R Hodgkin lymphoma
Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, presents the results of the Phase IIb randomized prospective clinical trial BRESELIBET (NCT04378647) investigating salvage chemotherapy alone (ESHAP) or supplemented with brentuximab vedotin (BRESHAP) in patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL). Patients receiving BRESHAP achieved significantly higher metabolic complete remission (mCR) rates, with no difference in toxicity profiles and the success of stem cell collection for autologous stem cell transplantation (autoSCT) between the groups. This study assessed brentuximab vedotin single drug consolidation therapy as an alternative to autoSCT in patients achieving mCR. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Takeda: Consultancy, Honoraria, Research Funding, Speakers Bureau; BMS/Celgene: Consultancy, Honoraria, Research Funding; MSD: Consultancy, Honoraria; Kite: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Jannsen: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria; GenMab: Consultancy, Honoraria; Pierre Fabre: Consultancy, Honoraria; Astra Zeneca: Consultancy, Honoraria.
